Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Clin Cancer Res. 2017 Aug 1;23(21):6567–6579. doi: 10.1158/1078-0432.CCR-17-1574

Fig. 6. The combination of AZD9291 and GSK1120212 effectively inhibits the growth of HCC827/AR and PC-9/AR xenografts in vivo (A and B) with limited toxicity (C) and modulation of Bim and Mcl-1 levels (D and E).

Fig. 6

HCC827/AR or PC-9/AR xenografts were treated (once a day) with vehicle control, AZD9291, GSK1120212 (GSK212) and their combination starting on the same day after grouping for 27 consecutive days (HCC827/AR) or following the intermittent treatment schedules indicated by arrows for 3 weeks (PC-9/AR). Tumor sizes were measured as indicated (A). Each measurement is mean ± SEM (n = 5). At the end of the treatment, the mice were sacrificed and the tumors were removed and weighed (B). Mouse body weights were also compared (C). * P < 0.05 at least compared with all other groups; ** P < 0.01 at least compared with all other groups; *** P < 0.001 at least compared with all other groups. D and E, Whole-protein cell lysates were prepared randomly from 3 tumors in each group for Western blotting to detect the indicated proteins. Band intensities were quantified with NIH Image J software.